CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Neovascular Age-related Macular Degeneration(nAMD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Eye & ENT Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Gezhi Xu, PhD) · drxugezhi@163.com · +86 18017316316
Tianjin Medical University Eye Hospital, Tianjin, Tianjing, China
Contact: Study coordinator (Xiaorong Li, PhD) · Xiaorli@163.com · +86 18622818042

Study leads

Study Director
Huidagene Therapeuticd Co., Ltd.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Abroad (travel likely)RecruitingPHASE1

Sydney, Australia · Sydney, Australia

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Neovascular Age-related Macular Degeneration

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Shanghai, China

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Neovascular Age-related Macular Degeneration

Abroad (travel likely)RecruitingPHASE2

Shanghai, China